Pendal Group’s Integra LifeSciences IART Stock Holding History

Pendal Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,500	Closed	-$307K	–	612
2021 Q2	$307K	Buy	+4,500	New	+$318K	﹤0.01%	493

Other funds holding IART

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pendal Group's IART Position: Q3 2021 in Review

Pendal Group sold out of Integra LifeSciences (IART) in Q3 2021, closing a stake of 4,500 shares — an estimated $307K sold.

Pendal Group first reported a position in IART in Q2 2021 and held it in 1 quarter. The position peaked at $307K in Q2 2021. 261 funds tracked by Wall St. Rank hold IART as of Q3 2021.

Pendal Group reported no remaining Integra LifeSciences position as of Q3 2021 after selling out during the quarter.
Pendal Group sold 4,500 Integra LifeSciences shares in Q3 2021, an estimated $307K.
Pendal Group first reported a position in Integra LifeSciences in Q2 2021 and held it in 1 quarter.
Pendal Group's Integra LifeSciences position peaked at $307K in Q2 2021.
261 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2021.

Based on Pendal Group's 13F filing for Q3 2021, filed 5 Nov 2021.